Any current/future new fundraising through debt or equity?

No explicit mention of any immediate new fundraising through debt or equity in the transcript. Current capex for FY24 was around INR 650 crores, FY25 anticipated INR 400-600 crores, funded through existing debt and internal accruals. Debt levels have increased mainly due to acquisitions and ongoing projects like Thane, Bangalore, Nashik; total debt still being managed within a debt-equity target of 0.7 and debt-EBITDA of 1.5. Management emphasizes disciplined capital deployment with preference for asset-light O&M (operations and management) contracts with buyback options to limit capital infus

Any current/future capex/capital investment/strategic investment?

FY24 capex incurred was approximately INR 650 crore, including land and building at Thane. FY25 anticipated capex is between INR 400 crore and INR 600 crore. Key projects include Bangalore (2 hospitals: 450-bed Marathahalli and 300-bed South Bangalore), Thane, Nashik, and Kondapur expansions. Bangalore hospital (Marathahalli) cost ~INR 1 crore/bed; South Bangalore hospital is on a revenue-share model with INR 70-80 lakh/bed. Thane hospital total capex expected around INR 515 crore, with potential to add 150 beds in Phase 2 at lower cost. Kondapur expansion divided into two phases: incremental

Future growth expectations in sales/revenue/volumes?

KIMS expects a steady revenue growth of around 10% year-on-year for mature hospitals and clusters like Telangana and Andhra Pradesh (AP), driven by volume growth, price hikes, and case mix improvements. Volume growth in AP inpatient services is around 6%, with overall cluster growth aided by new specialties and bed additions. New bed capacity additions, e.g., 100 incremental beds in Kondapur Phase 1 by Q1 FY '26 and full 500-550 beds by Q1 FY '27, are expected to boost revenue. The ramp-up of new doctors, especially in Telangana and AP clusters, is expected to accelerate growth reaching around

Future growth expectations in earnings/operating earnings/profits/EPS?

KIMS aims for steady revenue growth around 10% year-on-year in mature clusters (AP-Telangana), with some years experiencing 20-25% growth due to bed capacity additions and new specialties. Operating margins: Telangana cluster expected to stabilize at ~32% EBITDA margin net of one-off costs; Sunshine at ~26.5% moving upward; Nagpur starting at ~18.5% and improving with ramp-up. Incremental revenue in mature hospitals translates to 30-40% EBITDA flow-through. New hospitals (Bangalore, Thane, Nashik) modeled with loss funding capped around INR 10 crores per facility, with Nashik expected to

IN US

Sale is live|00:00:00left today

Krishna Institute of Medical Sciences LtdQ1 FY24Healthcare Services

Krishna Institute of Medical Sciences Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹797P/E: 122.9Market Cap: ₹30.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→KIMS expects a steady revenue growth of around 10% year-on-year for mature hospitals and clusters like Telangana and Andhra Pradesh (AP), driven by volume growth, price hikes, and case mix improvements.
→Volume growth in AP inpatient services is around 6%, with overall cluster growth aided by new specialties and bed additions.
→New bed capacity additions, e.g., 100 incremental beds in Kondapur Phase 1 by Q1 FY '26 and full 500-550 beds by Q1 FY '27, are expected to boost revenue.
→The ramp-up of new doctors, especially in Telangana and AP clusters, is expected to accelerate growth reaching around 15-20% in some quarters.
→Sunshine and Nagpur hospitals are showing encouraging growth with plans for revenue expansion and margin improvement.
→Pricing adjustments with insurance companies, including a potential 20-30% hike from GIPSA, will contribute to revenue growth.
→Overall, KIMS targets a consistent 10% revenue growth with occasional higher growth during capacity expansions.

Margin guidance

Category 3

→KIMS aims for steady revenue growth around 10% year-on-year in mature clusters (AP-Telangana), with some years experiencing 20-25% growth due to bed capacity additions and new specialties.
→Operating margins: Telangana cluster expected to stabilize at ~32% EBITDA margin net of one-off costs; Sunshine at ~26.5% moving upward; Nagpur starting at ~18.5% and improving with ramp-up.
→Incremental revenue in mature hospitals translates to 30-40% EBITDA flow-through.
→New hospitals (Bangalore, Thane, Nashik) modeled with loss funding capped around INR 10 crores per facility, with Nashik expected to breakeven within a year.
→Kondapur expansion phased: 100 beds added in FY26 with full 500-550 beds operational by Q1 FY27, driving growth.
→Price hikes on insurance contracts averaging 10-12% anticipated, with potential 20-30% hike in major contracts like GIPSA pending.
→Debt levels managed to maintain debt/EBITDA ratio around 1.5, ensuring financial discipline.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No explicit mention of any immediate new fundraising through debt or equity in the transcript.
→Current capex for FY24 was around INR 650 crores, FY25 anticipated INR 400-600 crores, funded through existing debt and internal accruals.
→Debt levels have increased mainly due to acquisitions and ongoing projects like Thane, Bangalore, Nashik; total debt still being managed within a debt-equity target of 0.7 and debt-EBITDA of 1.5.
→Management emphasizes disciplined capital deployment with preference for asset-light O&M (operations and management) contracts with buyback options to limit capital infusion.
→Future debt repayment expected after FY26 as existing projects stabilize; no indication of additional fundraise planned before then.
→The company appears focused on controlling leverage rather than raising new equity or debt in the near term.

Order book

The transcript does not explicitly mention specific details regarding current or expected order book or pending orders for KIMS Hospital. However, relevant insights can be inferred: - KIMS is undertaking multiple expansion projects including Kondapur (550 incremental beds by FY27 Q1), Thane hospital (290 beds commissioning by Q4 FY25), and new hospitals in Bangalore and Nashik. - There is active capacity addition and brownfield expansion planned across Telangana and Andhra Pradesh with around 50-100 bed additions per facility in Andhra. - These projects indicate a strong pipeline of capital expenditure and capacity expansion with phased commissioning. - Discussions also mention ongoing hirings and specialty additions implying service expansion. - Financially, sizeable capex is planned with targets to maintain comfortable debt-EBITDA ratios. No direct order book value or specific pending order figures were disclosed in the transcript.

Capex plans

Yes

→FY24 capex incurred was approximately INR 650 crore, including land and building at Thane.
→FY25 anticipated capex is between INR 400 crore and INR 600 crore.
→Key projects include Bangalore (2 hospitals: 450-bed Marathahalli and 300-bed South Bangalore), Thane, Nashik, and Kondapur expansions.
→Bangalore hospital (Marathahalli) cost ~INR 1 crore/bed; South Bangalore hospital is on a revenue-share model with INR 70-80 lakh/bed.
→Thane hospital total capex expected around INR 515 crore, with potential to add 150 beds in Phase 2 at lower cost.
→Kondapur expansion divided into two phases: incremental 100 beds commissioned early FY26 and full 500-550 beds by Q1 FY27.
→Strategy favors asset-light models and partnerships to limit capital commitment.
→Debt repayments expected to start post FY26 with target debt-to-equity of 0.7 and debt-to-EBITDA of 1.5.

How does Krishna Institute of Medical Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

1Krishna Institute of Medical Sciences Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Krishna Institute of Medical Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio